---
layout: default
title: Modafinil
parent: 僅模型預測 (L5)
nav_order: 96
evidence_level: L5
indication_count: 1
---

# Modafinil
{: .fs-9 }

證據等級: **L5** | 預測適應症: **1** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Modafinil: Repurposing Evaluation — Pending Complete Evidence Pack

## One-Sentence Summary

Modafinil (DrugBank ID: DB00745) is a drug currently not approved or marketed in Sweden.
This Evidence Pack is **incomplete**: no TxGNN predicted indications, no original indication data, and no safety records were successfully retrieved.
A full repurposing evaluation cannot be conducted until the critical data gaps identified below are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in current Evidence Pack |
| Predicted New Indication | No TxGNN predictions retrieved |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 (model prediction not yet available) |
| Sweden Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

This section cannot be completed at this time.

The Evidence Pack currently contains no mechanism of action (MOA) data and no predicted indications from the TxGNN model. Without a predicted target indication or mechanistic rationale, it is not possible to assess whether a repurposing hypothesis is biologically plausible.

Once the TxGNN output and MOA data are retrieved, this section will be populated to explain the relationship between the original and proposed new indication and why the drug's mechanism may extend to the new disease context.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for a repurposing direction, as no predicted indication has been identified in this Evidence Pack.

---

## Literature Evidence

Currently no related literature available, as no predicted indication has been identified in this Evidence Pack.

---

## Sweden Market Information

Modafinil has **no approved authorizations** in Sweden. No license records are available to display.

---

## Safety Considerations

Please refer to the package insert for safety information.

The DDI query returned no results, and TFDA package insert warnings and contraindications were not successfully parsed into this Evidence Pack. Safety evaluation cannot proceed until this data is retrieved.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This Evidence Pack is structurally incomplete — it contains no predicted indications, no original indication history, and no safety data. Proceeding to evaluation without these elements would produce unreliable conclusions.

**To proceed, the following is needed:**

- **[Critical — Blocking]** Retrieve and parse TFDA package insert PDF to extract approved indications, key warnings, and contraindications
- **[High Priority]** Query DrugBank API to obtain mechanism of action (MOA) and drug categories
- **[High Priority]** Re-run TxGNN pipeline for DB00745 to generate predicted indications with confidence scores
- **[Standard]** Once a predicted indication is confirmed, query ClinicalTrials.gov and PubMed for supporting evidence
- **[Standard]** Re-run DDI query once indication context is available to identify relevant drug-drug interactions

> **Note:** All findings from this report are for research reference only and do not constitute medical advice. Any drug repurposing candidate must be validated through clinical trials before application.
## Ansvarsfriskrivning

Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning.
Klinisk validering krävs före klinisk tillämpning.

---

